Healthcare DIVE May 3, 2024
Under the deal, Walgreens will find candidates who are overweight or have obesity or diabetes and connect them with a Phase III clinical trial for Boehringer’s GLP-1 drug survodutide.
Dive Brief:
- Walgreens has inked a clinical trial deal with major German drugmaker Boehringer Ingelheim.
- Under the deal, Walgreens will find candidates who are overweight or have obesity or diabetes and connect them with a Phase III clinical trial for Boehringer’s GLP-1 drug survodutide, according to a release.
- Walgreens launched its clinical trials business in 2022 as part of the company’s broader pivot to health services. Since then, Walgreens has notched more than 35 clinical trials deals with life sciences companies, according to a spokesperson.
Dive Insight:
A number...
Today's Sponsors
Today's Sponsor